SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 24.31-0.9%Oct 29 3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: vestor who wrote (1696)8/8/2001 8:05:30 PM
From: Sonki  Read Replies (2) of 1722
 
is there a basket or mutual fund for generics? update on pharmas..
Benefits to Statin Producers : --Intraday-- UBS Warburg comments on several pharmaceuticals after Bayer announces the withdrawal of its cholesterol lowering therapy Baycol from both U.S. and European markets due to reports of muscle tissue breakdown and weakness; Baycol would have generated $800 mln to $1 bln; brokerage estimates that based on current U.S. market share, 50% of this revenue ($500 mln) would go to Pfizer's (PFE) Lipitor, 20% ($200 mln) to Merck's (MRK) Zocor and 10% ($125 mln) to Bristol-Meyers Squib's (BMY) Pravachol; clearly upside to PFE and MRK and increases the chance they can beat estimates and may help BMY make their numbers; continues to rate PFE a STRONG BUY, MRK a BUY, and BMY a HOLD
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext